<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00681759</url>
  </required_header>
  <id_info>
    <org_study_id>D961FC00004</org_study_id>
    <nct_id>NCT00681759</nct_id>
  </id_info>
  <brief_title>An Observational Study of Burden of Upper GI-Symptoms in CV Risk Patients</brief_title>
  <official_title>A Prospective Descriptive, Multi-National, Multi-Centre Observational Study of Burden of Upper GI-Symptoms in Subjects With Cardiovascular Risk or Disease Receiving Treatment With Low-Dose Aspirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the burden of upper gastrointestinal symptoms in
      patients with cardiovascular disease taking low dose aspirin
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cross-sectional survey, SitePro Survey Domains including; background, UGI screening, PPI and H2 blocker usage, interaction between UGI and LDA ,UGI symptoms, HADS, Morisky Medication Taking Behavior Scale, SF12, SSA-P</measure>
    <time_frame>Once at enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>EMA assessments including: Sleep, Mood, Activities, Eating/food,GI symptoms,GI coping strategies, Medication usage, Healthcare Utilization</measure>
    <time_frame>Four times daily for three months</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1836</enrollment>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients who have been prescribed Low Dose Aspirin (LDA) usage in the past 12 months, or those about to begin LDA, will complete a one-time in-office survey using an electronic personal digital assistant (PDA) device (termed SitePro).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>420 subjects stratified into three groups varying on length of time using Low Dose Aspirin (LDA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Up to 20 subjects from the three EMA groups will be interviewed to further debrief their experience with Low Dose Aspirin (LDA) and upper GI symptoms.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiovascular risk or disease receiving LDA treatment in specialist and
        primary care clinics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed written inform consent.

          -  Physician prescribed or recommended daily intake of Low Dose Aspirin (LDA) (75-325 mg
             daily) for cardiovascular disease prevention within the past 12 months.

          -  Established cardiovascular disease, such as CAD (CoronaryArtery Disease), previous TIA
             (Transient Ischemic Attack), ischemic stroke or subjects with known risk factors for
             cardiovascular disease without having experienced cardiovascular events

        Exclusion Criteria:

          -  Need for concomitant treatment with a non-ASA NSAID (Nonsteroidal Antiinflammatory
             Drugs) including acyclooxygenase-2 (COX-2) selective NSAID. Occasional use of up to 1
             day/week is allowed.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brentwood</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Laurent</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2008</study_first_submitted>
  <study_first_submitted_qc>May 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2008</study_first_posted>
  <last_update_submitted>October 30, 2008</last_update_submitted>
  <last_update_submitted_qc>October 30, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind, MD, Medical Science Director, Nexium</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Low Dose Aspirin (LDA)</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Low Dose Aspirin (LDA) use in in subjects with cardiovascular risk or disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

